SELINDA (R/R)

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP (SELINDA)

Study treatments

Selinexor will be administered orally on Day 1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy for 3 cycles:

• R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine)
• R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin)

Inclusion criteria

• Patients with any type of relapsed or refractory B-cell lymphoma
• Eligible to receive R-DHAOx or R-GDP regarding the investigator's opinion
• Who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma
• Patient must have measurable disease defined by at least one single node or tumor lesion > 1.5 cm
• Age ≥ 18 years and ≤ 70 years
• ECOG 0-2

Exclusion criteria

• Previous treatment with selinexor
• Known central nervous system or meningeal involvement by lymphoma

Participating sites

Institut Jules Bordet